38 results
424B3
KPRX
Kiora Pharmaceuticals Inc
28 Mar 24
Prospectus supplement
4:48pm
Open Innovation SAS (“TOI”) with respect to KIO-301. Under the agreement, we granted to TOI an exclusive, sublicensable license to develop, manufacture
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
25 Mar 24
Results of Operations and Financial Condition
7:03am
of non-infectious uveitis. The $16 million upfront payment from Kiora’s development and commercialization partnership with Théa Open Innovation (TOI
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
Capital, among others.
“This financing, combined with our agreement with Théa Open Innovation, demonstrates the confidence in our team and development
8-K
EX-99.1
dpk3dxo0u
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EX-10.1
ezv7m8
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
7jjq8
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EX-99.1
t51akg8b2i8tyl
21 Sep 23
Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years
7:00am
8-K
EX-99.1
bl2ujjzscynnkbz
15 Jun 23
Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201
4:59pm
424B1
09lf0fgaldeop tecmk
2 Jun 23
Prospectus with pricing info
5:08pm
424B3
ypysw24w
28 Dec 22
Prospectus supplement
4:48pm
424B1
5tm6dyb9
22 Jul 22
Prospectus with pricing info
6:00pm